TABLE 2.
Implementation of Hib vaccine in countries of the WHO European Regiona
| Country | Yr of introduction | NIP | Formulation in 2019 | Schedule in 2019 | Coverage of Hib3 in 2019 (%) | Yr in which coverage reached ≥50% |
|---|---|---|---|---|---|---|
| Albania | 2009 | Yes | DTwP/Hib/HepB | 2, 4, 6 mo | 99 | 2009 |
| Andorra | 1999 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 12 mo | 98 | 1999 |
| Armenia | 2009 | Yes | DTwP/Hib/HepB | 6, 12, 18 wks | 92 | 2011 |
| DTaP/Hib/HepB/IPV | 18 mo | |||||
| Austria | 1994 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 11 mo | 85 | 1999 |
| Azerbaijan | 2011 | Yes | DTwP/Hib/HepB | 2, 3, 4 mo | 94 | 2012 |
| Belarus | 2018 | Yes | DTwP/Hib/HepB | 2, 3, 4 mo | 91 | 2018 |
| Hib | 1–4 yrs | |||||
| Belgium | 1993 | Yes | DTaP/Hib/HepB/IPV | 8, 12, 16 wks, 15 mo | 97 | 1999 |
| Bosnia and Herzegovina | 2008 | Yes | DTaP/Hib/IPV | 2, 4, 10 mo (3, 4, 18, 24 mo in Republic of Srpska/Brcko District) | 62 | 2005 |
| Bulgaria | 2010 | Yes | DTaP/Hib/HepB/IPV | 2, 3, 4 mo | 92 | 2010 |
| DTaP/Hib/IPV | 2, 3, 4, 18 mo | |||||
| Croatia | 2002 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 6, 18 mo | 94 | 2002 |
| Cyprus | 2001 | Yes | Hib | 2, 4, 6, 12–18 mo | 92 | 2003 |
| Czech Republic | 2001 | Yes | DTaP/Hib/HepB/IPV | 3, 5, 11 mo | 97 | 2002 |
| Denmark | 1993 | Yes | DTaP/Hib/IPV | 3, 5, 12 mo | 97 | 1993 |
| Estonia | 2005 | Yes | DTaP/Hib/HepB/IPV | 3, 4, 5, 6 mo, 2 yrs | 91 | 2006 |
| Hib (for children with contraindication for pertussis) | 3, 4, 6 mo, 2 yrs | |||||
| Finland | 1986 | Yes | DTaP/Hib/IPV | 3, 5, 12 mo | 91 | 1992 |
| France | 1992 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 11 mo | 95 | 1998 |
| Georgia | 2010 | Yes | DTaP/Hib/HepB/IPV | 2, 3, 4 mo | 94 | 2010 |
| Germany | 1990 | Yes | DTaP/Hib/HepB/IPV | 2, 3, 4, 11–14 mo | 92 | 1991 |
| Greece | 2000 | Yes | Hib (in various combination vaccines) | 2, 4, 6, 15–18 mo | 99 | 1997 |
| Hungary | 1999 | Yes | DTaP/Hib/IPV | 2, 3, 4, 18 mo | 99 | 1999 |
| Iceland | 1989 | Yes | DTaP/Hib/IPV | 3, 5, 12 mo | 91 | 1991 |
| Ireland | 1992 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 6 mo | 94 | 1997 |
| Hib (plus all high-risk groups) | 13 mo | |||||
| Israel | 1994 | Yes | DTaP/Hib/IPV | 2, 4, 6, 12 mo | 98 | 1994 |
| Italy | 1999 | Yes | DTaP/Hib/HepB/IPV | 3, 5, 11 mo | 95 | 2000 |
| Kazakhstan | 2008 | Yes | DTaP/Hib/HepB/IPV | 2, 4 mo | 97 | 2009 |
| DTaP/Hib/IPV | 3, 18 mo | |||||
| Kyrgyzstan | 2009 | Yes | DTwP/Hib/HepB | 2, 3, 5 mo | 94 | 2010 |
| Latvia | 1994 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 6, 12–15 mo | 99 | 1999 |
| DTaP/Hib/IPV (infants who receive monovalent HepB due to HepB risk from mother) | 2, 4, 6 mo | |||||
| Lithuania | 2004 | Yes | DTaP/Hib/IPV | 2, 4, 6, 18 mo | 92 | 2005 |
| Luxembourg | 1994 | Yes | DTaP/Hib/HepB/IPV | 2, 3, 13 mo | 99 | 1997 |
| DTaP/Hib/IPV | 4 mo | |||||
| Malta | 1996 | Yes | DTaP/Hib/HepB/IPV | 6–8 wks, 3, 4, 18 mo | 97 | 1997 |
| Monaco | 1992 | Yes | Hib | 2, 4, 11 mo | 99 | 1999 |
| Montenegro | 2006 | Yes | DTaP/Hib/IPV | 9, 17, 23 wks | 86 | 2006 |
| Hib | 18 mo | |||||
| Netherlands | 1993 | Yes | DTaP/Hib/HepB/IPV | 2, 3, 4–11 mo | 94 | 1997 |
| North Macedonia | 2008 | Yes | DTaP/Hib/HepB/IPV | 2, 6 mo | 92 | 2009 |
| DTaP/Hib/IPV | 3, 5, 18 mo | |||||
| Norway | 1992 | Yes | DTaP/Hib/HepB/IPV | 3, 5, 12 mo | 97 | 1996 |
| Poland | 2007 | Yes | DTaP/Hib/IPV (infants who receive HepB monovaccine due to HepB risk from mother) | 7–8 wks, 3–4, 5–6, 16–18 mo | 95 | 2007 |
| Hib | 2, 3–4, 5–6, 16–18 mo | |||||
| Portugal | 2000 | Yes | DTaP/Hib/HepB/IPV | 2, 6 mo | 99 | 1998 |
| DTaP/Hib/IPV | 18 mo | |||||
| Republic of Moldova | 2009 | Yes | DTwP/Hib/HepB | 2, 4, 6 mo | 92 | 2010 |
| Romania | 2010 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 11 mo | 86 | 2011 |
| Russian Federation | NO | DTaP/Hib/HepB/IPV | 3, 4.5, 6, 18 mo | Risk groups | ||
| DTaP/Hib/IPV | 3, 4.5, 6, 18 mo | |||||
| Hib | 3, 4.5, 6, 18 mo | |||||
| San Marino | 1996 | Yes | DTaP/Hib/HepB/IPV; Hib (risk groups) | 3, 5, 11 mo | 91 | 1991 |
| Serbia | 2006 | Yes | DTaP/Hib/IPV | 8, 10, 14 wks, 18 mo | 96 | 2007 |
| Slovakia | 2000 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 10 mo | 96 | 2000 |
| Slovenia | 2000 | Yes | DTaP/Hib/HepB/IPV; Hib (risk groups) | 3, 4, 5, 6, 18 mo | 93 | 2001 |
| Spain | 1998 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 11 mo | 94 | 1998 |
| Sweden | 1992 | Yes | DTaP/Hib/HepB/IPV | 3, 5, 12 mo | 97 | 1991 |
| Switzerland | 1990 | Yes | DTaP/Hib/HepB/IPV | 2, 4, 6, 15–24 mo | 95 | 1998 |
| DTaP/Hib/IPV | 2, 4, 6, 15–24 mo | |||||
| Hib | 2, 4, 6, 15–24 mo | |||||
| Tajikistan | 2008 | Yes | DTwP/Hib/HepB | 2, 3, 4 mo | 96 | 2009 |
| Turkey | 2006 | Yes | DTaP/Hib/IPV | 2, 4, 6, 18 mo | 98 | 2007 |
| Turkmenistan | 2010 | Yes | DTwP/Hib/HepB | 2, 3, 4 mo | 99 | 2010 |
| Ukraine | 2006 | Yes | DTwP/Hib/HepB | 2, 4, 12 mo | 39 | 2008, then declined |
| United Kingdom | 1992 | Yes | DTaP/Hib/HepB/IPV | 8, 12, 16 wks | 94 | 1993 |
| Hib/MenC | 1 yr | |||||
| Uzbekistan | 2009 | Yes | DTwP/Hib/HepB | 2, 3, 4 mo | 98 | 2009 |
a
Annual birth cohort, 11.1 million. Children aged <5 years, 56.4 million. Seventy-nine percent of target population was immunized with three doses of Hib (Hib3) in 2019 (based on WHO-UNICEF estimates) (100). NIP, national immunization program. Abbreviations of vaccine antigens: D, diphtheria; T, tetanus; aP, acellular pertussis; wP, whole-cell pertussis; Hib, Haemophilus influenzae type b; HepB, hepatitis B virus surface antigen; IPV, inactivated poliovirus; MenC, meningococcal serogroup C.